Sanofi has appointed Paulo Fontoura as its new head of research and development, tapping the Xaira executive to lead a turnaround effort. The move comes as the French pharmaceutical giant works to jumpstart its pipeline after a series of setbacks.
Fontoura's arrival signals a strategic shift for Sanofi, which has faced mounting pressure from investors to deliver on promising drug candidates. The company has struggled with high-profile failures and delays in recent months, prompting the leadership change.
According to STAT News, Fontoura was most recently chief medical officer at Xaira, a biotech firm. No financial terms of the appointment were disclosed in the source article.
The new R&D head will inherit a portfolio that includes several late-stage trials and early-stage programs. Sanofi's ability to bring new drugs to market will now hinge on Fontoura's leadership and strategic decisions in the coming quarters.
Analysts have noted the challenge of revitalizing a large pharma pipeline, but Fontoura's experience at Xaira could bring fresh perspective. The appointment marks another chapter in Sanofi's ongoing restructuring efforts.